ARCA biopharma Shares Published Paper Showing Trial Results

Biotech Investing

ARCA biopharma announced the publication of a paper showing GENETIC-AF Phase 2B trial results.

ARCA biopharma (NASDAQ:ABIO) announced the publication of a paper showing GENETIC-AF Phase 2B trial results.

As quoted in the press release:

ARCA biopharma, a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that the paper “GENETIC-AF: Bucindolol for the Maintenance of Sinus Rhythm in a Genotype-Defined Heart Failure Population” was published in JACC: Heart Failure, a journal of the American College of Cardiology.

“Atrial fibrillation (AF) is a common and serious medical problem associated with significant morbidity and mortality, especially in patients with heart failure (HF),” said Dr. Michael R. Bristow, President and Chief Executive Officer of ARCA and a co-author on the paper. “Development of AF is associated with increased risk of adverse cardiovascular outcomes, and when AF occurs in patients with HF these adverse effects are accentuated. AF and HF often co-exist and have common risk factors, as well as overlapping pathophysiologies.”

Click here to read the full press release.

The Conversation (0)
×